CytomX Therapeutics (STU:6C1) YoY EBITDA Growth : 290.14% (As of Mar. 2024)

View and export this data going back to 2016. Start your Free Trial

What is CytomX Therapeutics YoY EBITDA Growth?

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months. CytomX Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2024 was 290.14%.

CytomX Therapeutics's EBITDA per Share for the three months ended in Mar. 2024 was €0.14.

CytomX Therapeutics YoY EBITDA Growth Historical Data

The historical data trend for CytomX Therapeutics's YoY EBITDA Growth can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

CytomX Therapeutics YoY EBITDA Growth Chart

CytomX Therapeutics Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

YoY EBITDA Growth

Get a 7-Day Free Trial

-71.99

49.62

-12.60

9.21

96.20

CytomX Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
YoY EBITDA Growth	Get a 7-Day Free Trial															83.75	91.06	109.42	99.21	290.14

CytomX Therapeutics YoY EBITDA Growth Calculation

YoY EBITDA Growth is the percentage change of EBITDA per Share over the past twelve months.

CytomX Therapeutics's YoY EBITDA Growth for the fiscal year that ended in Dec. 2023 is calculated as:

	YoY EBITDA Growth (A: Dec. 2023 )
=	(EBITDA per Share (A: Dec. 2023 )	-	EBITDA per Share (A: Dec. 2022 ))	/	\| EBITDA per Share (A: Dec. 2022 ) \|
=	(-0.054	-	-1.42)	/	\| -1.42 \|
=	96.20 %

CytomX Therapeutics's YoY EBITDA Growth for the quarter that ended in Mar. 2024 is calculated as:

	YoY EBITDA Growth (Q: Mar. 2024 )
=	(EBITDA per Share (Q: Mar. 2024 )	-	EBITDA per Share (Q: Mar. 2023 ))	/	\| EBITDA per Share (Q: Mar. 2023 )) \|
=	(0.135	-	-0.071)	/	\| -0.071 \|
=	290.14 %

CytomX Therapeutics YoY EBITDA Growth Related Terms

Thank you for viewing the detailed overview of CytomX Therapeutics's YoY EBITDA Growth provided by GuruFocus.com. Please click on the following links to see related term pages.

CytomX Therapeutics (STU:6C1) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » CytomX Therapeutics Inc (STU:6C1) » Definitions » YoY EBITDA Growth

Comparable Companies

Traded in Other Exchanges

CTMX:USA 6C1:Germany

Address

151 Oyster Point Boulevard, Suite 400, South San Francisco, CA, USA, 94080

Website

https://www.cytomx.com

CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company which is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platform. The company probody technology platform to create proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.

CytomX Therapeutics (STU:6C1) Headlines

No Headlines